{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:58:44Z","timestamp":1761872324548,"version":"build-2065373602"},"reference-count":195,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,21]],"date-time":"2024-07-21T00:00:00Z","timestamp":1721520000000},"content-version":"am","delay-in-days":355,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01CA236722","R01CA265929","R37CA233476"],"award-info":[{"award-number":["R01CA236722","R01CA265929","R37CA233476"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["6640-22"],"award-info":[{"award-number":["6640-22"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.clml.2023.04.007","type":"journal-article","created":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T11:34:15Z","timestamp":1681904055000},"page":"561-574","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["SOHO State of the Art Updates and Next Questions | New Pathways and New Targets in PTCL: Staying on Target"],"prefix":"10.1016","volume":"23","author":[{"given":"Shannon A.","family":"Carty","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos A.","family":"Murga-Zamalloa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6420-0760","authenticated-orcid":false,"given":"Ryan A.","family":"Wilcox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.clml.2023.04.007_bib0001","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2023.04.007_bib0002","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00428-022-03412-6","article-title":"Classification and diagnostic evaluation of nodal T- and NK-cell lymphomas","volume":"482","author":"Feldman","year":"2023","journal-title":"Virchows Arch"},{"issue":"10","key":"10.1016\/j.clml.2023.04.007_bib0003","doi-asserted-by":"crossref","first-page":"e765","DOI":"10.1016\/S2352-3026(20)30207-6","article-title":"The peripheral T-cell lymphomas: an unusual path to cure","volume":"7","author":"Ma","year":"2020","journal-title":"Lancet Haematol"},{"issue":"2","key":"10.1016\/j.clml.2023.04.007_bib0004","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.blre.2015.08.003","article-title":"Genomic signatures in T-cell lymphoma: How can these improve precision in diagnosis and inform prognosis?","volume":"30","author":"Iqbal","year":"2016","journal-title":"Blood Rev"},{"issue":"11","key":"10.1016\/j.clml.2023.04.007_bib0005","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41408-022-00745-y","article-title":"GATA-3 is a proto-oncogene in T-cell lymphoproliferative neoplasms","volume":"12","author":"Geng","year":"2022","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1016\/j.clml.2023.04.007_bib0006","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1158\/1078-0432.CCR-16-1996","article-title":"T-cell receptor signaling activates an ITK\/NF-kappaB\/GATA-3 axis in T-cell lymphomas facilitating resistance to chemotherapy","volume":"23","author":"Wang","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.clml.2023.04.007_bib0007","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/hon.2705","article-title":"Survival benefit in patients with peripheral T-cell lymphomas after treatments with novel therapies and clinical trials","volume":"38","author":"Ma","year":"2020","journal-title":"Hematol Oncol"},{"issue":"1","key":"10.1016\/j.clml.2023.04.007_bib0008","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1182\/hematology.2020000101","article-title":"Strategies for aggressive T-cell lymphoma: divide and conquer","volume":"2020","author":"Pinter-Brown","year":"2020","journal-title":"Hematol Am Soc Educ Program"},{"issue":"7","key":"10.1016\/j.clml.2023.04.007_bib0009","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1182\/blood.2021013568","article-title":"Whole-genome landscape of adult T-cell leukemia\/lymphoma","volume":"139","author":"Kogure","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2023.04.007_bib0010","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cell.2012.06.053","article-title":"Foxp3 exploits a pre-existent enhancer landscape for regulatory T cell lineage specification","volume":"151","author":"Samstein","year":"2012","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.clml.2023.04.007_bib0011","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.cell.2012.09.044","article-title":"STATs shape the active enhancer landscape of T cell populations","volume":"151","author":"Vahedi","year":"2012","journal-title":"Cell"},{"issue":"25","key":"10.1016\/j.clml.2023.04.007_bib0012","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1182\/blood-2014-06-582700","article-title":"Global transcriptome analysis and enhancer landscape of human primary T follicular helper and T effector lymphocytes","volume":"124","author":"Weinstein","year":"2014","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2023.04.007_bib0013","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1038\/s41375-020-0990-y","article-title":"Advances in understanding of angioimmunoblastic T-cell lymphoma","volume":"34","author":"Chiba","year":"2020","journal-title":"Leukemia"},{"issue":"24","key":"10.1016\/j.clml.2023.04.007_bib0014","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1182\/blood.2019000779","article-title":"Reproducing the molecular subclassification of peripheral T-cell lymphoma-NOS by immunohistochemistry","volume":"134","author":"Amador","year":"2019","journal-title":"Blood"},{"issue":"36","key":"10.1016\/j.clml.2023.04.007_bib0015","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.21.02707","article-title":"Gene expression signatures for the accurate diagnosis of peripheral T-cell lymphoma entities in the routine clinical practice","volume":"40","author":"Amador","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.04.007_bib0016","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1099265","article-title":"Classification and challenges in the histopathological diagnosis of peripheral T-cell lymphomas, emphasis on the WHO-HAEM5 updates","volume":"12","author":"Murga-Zamalloa","year":"2022","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.clml.2023.04.007_bib0017","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1600-0609.2012.01766.x","article-title":"The B7 homologues and their receptors in hematologic malignancies","volume":"88","author":"Wilcox","year":"2012","journal-title":"Eur J Haematol"},{"issue":"2","key":"10.1016\/j.clml.2023.04.007_bib0018","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ccell.2018.01.001","article-title":"RHOA G17V Induces T follicular helper cell specification and promotes lymphomagenesis","volume":"33","author":"Cortes","year":"2018","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.clml.2023.04.007_bib0019","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3324\/haematol.2009.010991","article-title":"The inducible T-cell co-stimulator molecule is expressed on subsets of T cells and is a new marker of lymphomas of T follicular helper cell-derivation","volume":"95","author":"Marafioti","year":"2010","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.clml.2023.04.007_bib0020","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-020-0301-x","article-title":"Bright PD-1 expression by flow cytometry is a powerful tool for diagnosis and monitoring of angioimmunoblastic T-cell lymphoma","volume":"10","author":"Yabe","year":"2020","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.clml.2023.04.007_bib0021","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.immuni.2018.06.012","article-title":"PD-1 controls follicular T helper cell positioning and function","volume":"49","author":"Shi","year":"2018","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.clml.2023.04.007_bib0022","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1097\/01.pas.0000209855.28282.ce","article-title":"Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma","volume":"30","author":"Dorfman","year":"2006","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"10.1016\/j.clml.2023.04.007_bib0023","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.3324\/haematol.10864","article-title":"Expression of two markers of germinal center T cells (SAP and PD-1) in angioimmunoblastic T-cell lymphoma","volume":"92","author":"Roncador","year":"2007","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.clml.2023.04.007_bib0024","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1309\/AJCP62WRKERPXDRT","article-title":"Germinal-center T-helper-cell markers PD-1 and CXCL13 are both expressed by neoplastic cells in angioimmunoblastic T-cell lymphoma","volume":"131","author":"Yu","year":"2009","journal-title":"Am J Clin Pathol"},{"issue":"17","key":"10.1016\/j.clml.2023.04.007_bib0025","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1182\/blood.2019002038","article-title":"Rapid progression of adult T-cell leukemia\/lymphoma as tumor-infiltrating Tregs after PD-1 blockade","volume":"134","author":"Rauch","year":"2019","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.clml.2023.04.007_bib0026","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1056\/NEJMc1803181","article-title":"Rapid progression of adult T-cell leukemia-lymphoma after PD-1 inhibitor therapy","volume":"378","author":"Ratner","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clml.2023.04.007_bib0027","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/ajh.24203","article-title":"A three-signal model of T-cell lymphoma pathogenesis","volume":"91","author":"Wilcox","year":"2016","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.clml.2023.04.007_bib0028","doi-asserted-by":"crossref","first-page":"943-58 e9","DOI":"10.1016\/j.immuni.2017.10.014","article-title":"Dichotomous expression of TNF superfamily ligands on antigen-presenting cells controls post-priming anti-viral CD4(+) T cell immunity","volume":"47","author":"Chang","year":"2017","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.clml.2023.04.007_bib0029","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1182\/blood-2003-06-2184","article-title":"Ligation of CD137 receptor prevents and reverses established anergy of CD8+ cytolytic T lymphocytes in vivo","volume":"103","author":"Wilcox","year":"2004","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2023.04.007_bib0030","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S1074-7613(01)00191-1","article-title":"OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells","volume":"15","author":"Rogers","year":"2001","journal-title":"Immunity"},{"issue":"14","key":"10.1016\/j.clml.2023.04.007_bib0031","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1182\/blood-2009-05-220111","article-title":"Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells","volume":"114","author":"Wilcox","year":"2009","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2023.04.007_bib0032","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1158\/2767-9764.CRC-22-0336","article-title":"Targeting Lymphoma-associated Macrophage Expansion via CSF1R\/JAK Inhibition is a Therapeutic Vulnerability in Peripheral T-cell Lymphomas","volume":"2","author":"Gao","year":"2022","journal-title":"Cancer Res Commun"},{"issue":"3","key":"10.1016\/j.clml.2023.04.007_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110695","article-title":"Oncogenic Vav1-Myo1f induces therapeutically targetable macrophage-rich tumor microenvironment in peripheral T cell lymphoma","volume":"39","author":"Cortes","year":"2022","journal-title":"Cell reports"},{"issue":"18","key":"10.1016\/j.clml.2023.04.007_bib0034","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1182\/blood.2022015451","article-title":"Clonal germinal center B cells function as a niche for T-cell lymphoma","volume":"140","author":"Fujisawa","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2023.04.007_bib0035","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1158\/1078-0432.CCR-19-1486","article-title":"Colony-Stimulating Factor 1 Receptor (CSF1R) activates AKT\/mTOR signaling and promotes T-cell lymphoma viability","volume":"26","author":"Murga-Zamalloa","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.clml.2023.04.007_bib0036","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1182\/blood-2017-11-818617","article-title":"RhoA G17V is sufficient to induce autoimmunity and promotes T-cell lymphomagenesis in mice","volume":"132","author":"Ng","year":"2018","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2023.04.007_bib0037","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1158\/0008-5472.CAN-21-1908","article-title":"Noncanonical Function of AGO2 Augments T-cell Receptor Signaling in T-cell Prolymphocytic Leukemia","volume":"82","author":"Braun","year":"2022","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.clml.2023.04.007_bib0038","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1182\/blood-2007-07-101519","article-title":"High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia","volume":"111","author":"Herling","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.04.007_bib0039","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12935-019-0754-9","article-title":"ITK inhibition induced in vitro and in vivo anti-tumor activity through downregulating TCR signaling pathway in malignant T cell lymphoma","volume":"19","author":"Liu","year":"2019","journal-title":"Cancer Cell Int"},{"issue":"1","key":"10.1016\/j.clml.2023.04.007_bib0040","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/s41392-021-00823-w","article-title":"T cell receptor (TCR) signaling in health and disease","volume":"6","author":"Shah","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"10.1016\/j.clml.2023.04.007_bib0041","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a002287","article-title":"T-cell signaling regulated by the Tec family kinase, Itk","volume":"2","author":"Andreotti","year":"2010","journal-title":"Cold Spring Harbor Perspect Biol"},{"key":"10.1016\/j.clml.2023.04.007_bib0042","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1034\/j.1600-065X.2003.00029.x","article-title":"The role of Tec family kinases in T cell development and function","volume":"191","author":"Lucas","year":"2003","journal-title":"Immunol Rev"},{"issue":"15","key":"10.1016\/j.clml.2023.04.007_bib0043","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1038\/onc.2016.366","article-title":"NPM-ALK phosphorylates WASp Y102 and contributes to oncogenesis of anaplastic large cell lymphoma","volume":"36","author":"Murga-Zamalloa","year":"2017","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.clml.2023.04.007_bib0044","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41388-020-01533-3","article-title":"Deficiency of Wiskott-Aldrich syndrome protein has opposing effect on the pro-oncogenic pathway activation in nonmalignant versus malignant lymphocytes","volume":"40","author":"Han","year":"2021","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.clml.2023.04.007_bib0045","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.4049\/jimmunol.174.3.1385","article-title":"Kinase-independent functions for Itk in TCR-induced regulation of Vav and the actin cytoskeleton","volume":"174","author":"Dombroski","year":"2005","journal-title":"J Immunol"},{"issue":"22","key":"10.1016\/j.clml.2023.04.007_bib0046","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2021108125","article-title":"Cancer-associated mutations in VAV1 trigger variegated signaling outputs and T-cell lymphomagenesis","volume":"40","author":"Robles-Valero","year":"2021","journal-title":"EMBO J"},{"issue":"9","key":"10.1016\/j.clml.2023.04.007_bib0047","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1158\/2159-8290.CD-15-0675","article-title":"Triggering the TCR developmental checkpoint activates a therapeutically targetable tumor suppressive pathway in T-cell leukemia","volume":"6","author":"Trinquand","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clml.2023.04.007_bib0048","doi-asserted-by":"crossref","first-page":"10087","DOI":"10.1038\/ncomms10087","article-title":"Anaplastic large cell lymphoma arises in thymocytes and requires transient TCR expression for thymic egress","volume":"7","author":"Malcolm","year":"2016","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.clml.2023.04.007_bib0049","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1084\/jem.20092042","article-title":"The fusion kinase ITK-SYK mimics a T cell receptor signal and drives oncogenesis in conditional mouse models of peripheral T cell lymphoma","volume":"207","author":"Pechloff","year":"2010","journal-title":"J Exp Med"},{"issue":"2","key":"10.1016\/j.clml.2023.04.007_bib0050","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/sj.leu.2404045","article-title":"Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma.[see comment]","volume":"20","author":"Streubel","year":"2006","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2023.04.007_bib0051","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1038\/s41467-021-24037-4","article-title":"Fusion transcripts FYN-TRAF3IP2 and KHDRBS1-LCK hijack T cell receptor signaling in peripheral T-cell lymphoma, not otherwise specified","volume":"12","author":"Debackere","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.clml.2023.04.007_bib0052","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s43018-020-00161-w","article-title":"FYN-TRAF3IP2 induces NF-kappaB signaling-driven peripheral T cell lymphoma","volume":"2","author":"Moon","year":"2021","journal-title":"Nat Cancer"},{"issue":"3","key":"10.1016\/j.clml.2023.04.007_bib0053","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1182\/blood-2007-04-084814","article-title":"Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation.[see comment]","volume":"111","author":"Schade","year":"2008","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2023.04.007_bib0054","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41416-019-0557-8","article-title":"Tyrosine kinase inhibition to improve anthracycline-based chemotherapy efficacy in T-cell lymphoma","volume":"121","author":"Magni","year":"2019","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.clml.2023.04.007_bib0055","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/leu.2017.273","article-title":"Activation of RHOA-VAV1 signaling in angioimmunoblastic T-cell lymphoma","volume":"32","author":"Fujisawa","year":"2018","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.clml.2023.04.007_bib0056","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1158\/0008-5472.CAN-19-2787","article-title":"Dasatinib is an effective treatment for angioimmunoblastic T-cell lymphoma","volume":"80","author":"Nguyen","year":"2020","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.clml.2023.04.007_bib0057","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/bjh.15702","article-title":"Phase I\/II study of dasatinib and exploratory genomic analysis in relapsed or refractory non-Hodgkin lymphoma","volume":"184","author":"Umakanthan","year":"2019","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.clml.2023.04.007_bib0058","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nbt1358","article-title":"A quantitative analysis of kinase inhibitor selectivity","volume":"26","author":"Karaman","year":"2008","journal-title":"Nat Biotechnol"},{"issue":"1","key":"10.1016\/j.clml.2023.04.007_bib0059","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1080\/14756366.2021.1937143","article-title":"New horizons in drug discovery of lymphocyte-specific protein tyrosine kinase (Lck) inhibitors: a decade review (2011-2021) focussing on structure-activity relationship (SAR) and docking insights","volume":"36","author":"Elkamhawy","year":"2021","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"6","key":"10.1016\/j.clml.2023.04.007_bib0060","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1038\/leu.2008.77","article-title":"Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas","volume":"22","author":"Feldman","year":"2008","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2023.04.007_bib0061","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/leu.2009.198","article-title":"Inhibition of Syk protein tyrosine kinase induces apoptosis and blocks proliferation in T-cell non-Hodgkin's lymphoma cell lines","volume":"24","author":"Wilcox","year":"2010","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2023.04.007_bib0062","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13045-017-0512-1","article-title":"Syk inhibitors in clinical development for hematological malignancies","volume":"10","author":"Liu","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"3","key":"10.1016\/j.clml.2023.04.007_bib0063","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1124\/jpet.114.218164","article-title":"The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer","volume":"351","author":"Coffey","year":"2014","journal-title":"J Pharmacol Exp Therapeut"},{"key":"10.1016\/j.clml.2023.04.007_bib0064","series-title":"Presented at the Annual Meeting of the","article-title":"A Phase 2 Study of the Dual SYK\/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed\/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma","author":"Horwitz","year":"2019"},{"issue":"1","key":"10.1016\/j.clml.2023.04.007_bib0065","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s13046-022-02352-y","article-title":"The role of TBK1 in cancer pathogenesis and anticancer immunity","volume":"41","author":"Runde","year":"2022","journal-title":"J Exp Clinical Cancer Res: CR"},{"issue":"7","key":"10.1016\/j.clml.2023.04.007_bib0066","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/ni.3463","article-title":"A TRAF-like motif of the inducible costimulator ICOS controls development of germinal center TFH cells via the kinase TBK1","volume":"17","author":"Pedros","year":"2016","journal-title":"Nat Immunol"},{"issue":"4","key":"10.1016\/j.clml.2023.04.007_bib0067","doi-asserted-by":"crossref","first-page":"E90","DOI":"10.1002\/ajh.25387","article-title":"Efficacy and safety of the dual SYK\/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study","volume":"94","author":"Hamlin","year":"2019","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.clml.2023.04.007_bib0068","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.4049\/jimmunol.176.3.1571","article-title":"Tec kinases Itk and Rlk are required for CD8+ T cell responses to virus infection independent of their role in CD4+ T cell help","volume":"176","author":"Atherly","year":"2006","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.clml.2023.04.007_bib0069","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.immuni.2006.05.012","article-title":"The Tec family tyrosine kinases Itk and Rlk regulate the development of conventional CD8+ T cells","volume":"25","author":"Atherly","year":"2006","journal-title":"Immunity"},{"issue":"11","key":"10.1016\/j.clml.2023.04.007_bib0070","doi-asserted-by":"crossref","first-page":"7561","DOI":"10.4049\/jimmunol.179.11.7561","article-title":"Subtle defects in pre-TCR signaling in the absence of the Tec kinase Itk","volume":"179","author":"Lucas","year":"2007","journal-title":"J Immunol"},{"issue":"19","key":"10.1016\/j.clml.2023.04.007_bib0071","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1182\/blood-2013-12-544809","article-title":"GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features","volume":"123","author":"Wang","year":"2014","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.clml.2023.04.007_bib0072","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1182\/blood-2013-11-536359","article-title":"Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma","volume":"123","author":"Iqbal","year":"2014","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.clml.2023.04.007_bib0073","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1182\/blood-2018-09-872549","article-title":"Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma","volume":"133","author":"Heavican","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.04.007_bib0074","series-title":"Presented at the Annual Meeting of the","article-title":"ITK Inhibition Induces Dose-Dependent Th1 Skewing in Normal T Cells and is Active in Refractory T-cell Lymphomas","author":"Song","year":"2022"},{"issue":"15","key":"10.1016\/j.clml.2023.04.007_bib0075","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","article-title":"Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes","volume":"122","author":"Dubovsky","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2023.04.007_bib0076","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clml.2023.04.007_bib0077","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1182\/bloodadvances.2017011916","article-title":"Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma","volume":"2","author":"Kumar","year":"2018","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.clml.2023.04.007_bib0078","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.immuni.2016.04.020","article-title":"CD28 Costimulation: from mechanism to therapy","volume":"44","author":"Esensten","year":"2016","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.clml.2023.04.007_bib0079","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/imr.12771","article-title":"Inducible T-cell co-stimulator: Signaling mechanisms in T follicular helper cells and beyond","volume":"291","author":"Panneton","year":"2019","journal-title":"Immunol Rev"},{"key":"10.1016\/j.clml.2023.04.007_bib0080","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1146\/annurev.immunol.23.021704.115839","article-title":"TNF\/TNFR family members in costimulation of T cell responses","volume":"23","author":"Watts","year":"2005","journal-title":"Annu Rev Immunol"},{"issue":"5","key":"10.1016\/j.clml.2023.04.007_bib0081","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/leu.2015.357","article-title":"Recurrent activating mutations of CD28 in peripheral T-cell lymphomas","volume":"30","author":"Rohr","year":"2016","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.clml.2023.04.007_bib0082","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/ng.3370","article-title":"Genomic analysis of mycosis fungoides and Sezary syndrome identifies recurrent alterations in TNFR2","volume":"47","author":"Ungewickell","year":"2015","journal-title":"Nat Gen"},{"issue":"2","key":"10.1016\/j.clml.2023.04.007_bib0083","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/mgg3.121","article-title":"Personalized treatment of Sezary syndrome by targeting a novel CTLA4:CD28 fusion","volume":"3","author":"Sekulic","year":"2015","journal-title":"Mol Genet Genomic Med"},{"issue":"8","key":"10.1016\/j.clml.2023.04.007_bib0084","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.jmoldx.2021.04.013","article-title":"Detection of gene fusion transcripts in peripheral T-cell lymphoma using a multiplexed targeted sequencing assay","volume":"23","author":"Drieux","year":"2021","journal-title":"J Mol Diagn"},{"issue":"10","key":"10.1016\/j.clml.2023.04.007_bib0085","doi-asserted-by":"crossref","first-page":"4984","DOI":"10.4049\/jimmunol.158.10.4984","article-title":"Sezary lineage cells can be induced to proliferate via CD28-mediated costimulation","volume":"158","author":"McCusker","year":"1997","journal-title":"J Immunol"},{"issue":"9","key":"10.1016\/j.clml.2023.04.007_bib0086","doi-asserted-by":"crossref","first-page":"5035","DOI":"10.4049\/jimmunol.165.9.5035","article-title":"Mouse inducible costimulatory molecule (ICOS) expression is enhanced by CD28 costimulation and regulates differentiation of CD4+ T cells","volume":"165","author":"McAdam","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.clml.2023.04.007_bib0087","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1146\/annurev.immunol.23.021704.115611","article-title":"The B7 family revisited","volume":"23","author":"Greenwald","year":"2005","journal-title":"Ann Rev Immunol"},{"issue":"3","key":"10.1016\/j.clml.2023.04.007_bib0088","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.4049\/jimmunol.181.3.1969","article-title":"ICOS ligation recruits the p50alpha PI3K regulatory subunit to the immunological synapse","volume":"181","author":"Fos","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.clml.2023.04.007_bib0089","series-title":"Presented at the Annual Meeting of the","article-title":"Duvelisib in patients with relapsed\/refractory peripheral T-cell lymphoma from the phase 2 primo trial: results of an interim analysis","author":"Brammer","year":"2021"},{"issue":"8","key":"10.1016\/j.clml.2023.04.007_bib0090","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1182\/blood-2017-08-802470","article-title":"Activity of the PI3K-delta,gamma inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma","volume":"131","author":"Horwitz","year":"2018","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2023.04.007_bib0091","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12082293","article-title":"Phase I\/Ib Study of Tenalisib (RP6530), a dual PI3K delta\/gamma inhibitor in patients with relapsed\/refractory T-Cell lymphoma","volume":"12","author":"Huen","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.clml.2023.04.007_bib0092","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/MOH.0000000000000254","article-title":"Oncogenic Notch signaling in T-cell and B-cell lymphoproliferative disorders","volume":"23","author":"Chiang","year":"2016","journal-title":"Curr Opin Hematol"},{"issue":"11","key":"10.1016\/j.clml.2023.04.007_bib0093","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.190187","article-title":"Notch signalling in T cell homeostasis and differentiation","volume":"9","author":"Brandstadter","year":"2019","journal-title":"Open Biol"},{"issue":"10","key":"10.1016\/j.clml.2023.04.007_bib0094","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1084\/jem.20061020","article-title":"The requirement for Notch signaling at the beta-selection checkpoint in vivo is absolute and independent of the pre-T cell receptor","volume":"203","author":"Maillard","year":"2006","journal-title":"J Exp Med"},{"issue":"11","key":"10.1016\/j.clml.2023.04.007_bib0095","doi-asserted-by":"crossref","first-page":"5818","DOI":"10.4049\/jimmunol.1203452","article-title":"T cell-specific notch inhibition blocks graft-versus-host disease by inducing a hyporesponsive program in alloreactive CD4+ and CD8+ T cells","volume":"190","author":"Sandy","year":"2013","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.clml.2023.04.007_bib0096","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1172\/JCI65477","article-title":"Blockade of individual Notch ligands and receptors controls graft-versus-host disease","volume":"123","author":"Tran","year":"2013","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.clml.2023.04.007_bib0097","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1182\/blood-2010-03-271940","article-title":"Notch signaling is a critical regulator of allogeneic CD4+ T-cell responses mediating graft-versus-host disease","volume":"117","author":"Zhang","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2023.04.007_bib0098","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.immuni.2014.12.027","article-title":"Notch signaling regulates antigen sensitivity of naive CD4+ T cells by tuning co-stimulation","volume":"42","author":"Laky","year":"2015","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.clml.2023.04.007_bib0099","doi-asserted-by":"crossref","first-page":"e67306","DOI":"10.1371\/journal.pone.0067306","article-title":"Gauging NOTCH1 activation in cancer using immunohistochemistry","volume":"8","author":"Kluk","year":"2013","journal-title":"PLoS One"},{"issue":"20","key":"10.1016\/j.clml.2023.04.007_bib0100","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1158\/0008-5472.CAN-22-1215","article-title":"Notch signaling promotes mature T-cell lymphomagenesis","volume":"82","author":"Gao","year":"2022","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.clml.2023.04.007_bib0101","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/s41385-018-0012-9","article-title":"Notch signaling represents an important checkpoint between follicular T-helper and canonical T-helper 2 cell fate","volume":"11","author":"Dell'Aringa","year":"2018","journal-title":"Mucosal Immunol"},{"issue":"5","key":"10.1016\/j.clml.2023.04.007_bib0102","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.4049\/jimmunol.1300643","article-title":"Notch signaling regulates follicular helper T cell differentiation","volume":"191","author":"Auderset","year":"2013","journal-title":"J Immunol"},{"issue":"10","key":"10.1016\/j.clml.2023.04.007_bib0103","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1182\/blood-2009-04-216671","article-title":"B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders","volume":"114","author":"Wilcox","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.04.007_bib0104","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-016-0201-6","article-title":"Challenges and opportunities for checkpoint blockade in T-cell lymphoproliferative disorders","volume":"4","author":"Phillips","year":"2016","journal-title":"J Immunother Cancer"},{"issue":"7683","key":"10.1016\/j.clml.2023.04.007_bib0105","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nature24649","article-title":"PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis","volume":"552","author":"Wartewig","year":"2017","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.clml.2023.04.007_bib0106","doi-asserted-by":"crossref","first-page":"7338","DOI":"10.1074\/jbc.M112.374967","article-title":"Signaling of the ITK (interleukin 2-inducible T cell kinase)-SYK (spleen tyrosine kinase) fusion kinase is dependent on adapter SLP-76 and on the adapter function of the kinases SYK and ZAP70","volume":"288","author":"Hussain","year":"2013","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.clml.2023.04.007_bib0107","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.4049\/jimmunol.1502643","article-title":"Genetic and epigenetic regulation of PD-1 expression","volume":"196","author":"Bally","year":"2016","journal-title":"J Immunol"},{"key":"10.1016\/j.clml.2023.04.007_bib0108","doi-asserted-by":"crossref","first-page":"43613","DOI":"10.1038\/srep43613","article-title":"Chromatin states shape insertion profiles of the piggyBac, Tol2 and Sleeping Beauty transposons and murine leukemia virus","volume":"7","author":"Yoshida","year":"2017","journal-title":"Sci Rep"},{"issue":"5502","key":"10.1016\/j.clml.2023.04.007_bib0109","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1126\/science.291.5502.319","article-title":"Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice","volume":"291","author":"Nishimura","year":"2001","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.clml.2023.04.007_bib0110","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.clml.2023.04.007_bib0111","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1097\/PAS.0b013e3181971591","article-title":"Peripheral T-cell lymphomas with a follicular growth pattern are derived from follicular helper T cells (TFH) and may show overlapping features with angioimmunoblastic T-cell lymphomas","volume":"33","author":"Huang","year":"2009","journal-title":"Am J Surg Pathol"},{"issue":"9","key":"10.1016\/j.clml.2023.04.007_bib0112","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1097\/PAS.0b013e3182991415","article-title":"Dogan A. ITK\/SYK translocation in angioimmunoblastic T-cell lymphoma","volume":"37","author":"Attygalle","year":"2013","journal-title":"Am J Surg Pathol"},{"issue":"22","key":"10.1016\/j.clml.2023.04.007_bib0113","doi-asserted-by":"crossref","first-page":"16124","DOI":"10.18632\/oncotarget.24592","article-title":"Overlap at the molecular and immunohistochemical levels between angioimmunoblastic T-cell lymphoma and a subgroup of peripheral T-cell lymphomas without specific morphological features","volume":"9","author":"Manso","year":"2018","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.clml.2023.04.007_bib0114","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1097\/PAS.0b013e31817f123e","article-title":"Peripheral T-cell lymphoma with follicular T-cell markers","volume":"32","author":"Rodriguez-Pinilla","year":"2008","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"10.1016\/j.clml.2023.04.007_bib0115","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/ni.1877","article-title":"PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells","volume":"11","author":"Good-Jacobson","year":"2010","journal-title":"Nat Immunol"},{"key":"10.1016\/j.clml.2023.04.007_bib0116","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.humpath.2019.05.007","article-title":"Recurrent PDL1 expression and PDL1 (CD274) copy number alterations in breast implant-associated anaplastic large cell lymphomas","volume":"90","author":"Tabanelli","year":"2019","journal-title":"Hum Pathol"},{"issue":"2","key":"10.1016\/j.clml.2023.04.007_bib0117","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3324\/haematol.2017.180430","article-title":"Epstein-Barr virus-associated primary nodal T\/NK-cell lymphoma shows a distinct molecular signature and copy number changes","volume":"103","author":"Ng","year":"2018","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.clml.2023.04.007_bib0118","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1080\/10428194.2021.1881511","article-title":"PD-L1 expression in peripheral T-cell lymphomas is not related to either PD-L1 gene amplification or rearrangements","volume":"62","author":"Manso","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1016\/j.clml.2023.04.007_bib0119","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1056\/NEJMc1807852","article-title":"PD-1 inhibitor therapy in adult T-cell leukemia-lymphoma","volume":"379","author":"Ishitsuka","year":"2018","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.clml.2023.04.007_bib0120","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1182\/blood-2018-01-824607","article-title":"North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies","volume":"132","author":"Shah","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.04.007_bib0121","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2019.03.022","article-title":"Phase II study of the PD-1 inhibitor pembrolizumab for the treatment of relapsed or refractory mature T-cell lymphoma","author":"Barta","year":"2019","journal-title":"Clin Lymph, Myel Leuk"},{"issue":"6","key":"10.1016\/j.clml.2023.04.007_bib0122","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004984","article-title":"Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression","volume":"10","author":"Bennani","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.clml.2023.04.007_bib0123","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13045-021-01033-1","article-title":"Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002)","volume":"14","author":"Shi","year":"2021","journal-title":"J Hematology Oncol"},{"issue":"38","key":"10.1016\/j.clml.2023.04.007_bib0124","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abd2712","article-title":"Revisiting the PD-1 pathway","volume":"6","author":"Patsoukis","year":"2020","journal-title":"Sci Adv"},{"issue":"43","key":"10.1016\/j.clml.2023.04.007_bib0125","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aay1863","article-title":"Targeted deletion of PD-1 in myeloid cells induces antitumor immunity","volume":"5","author":"Strauss","year":"2020","journal-title":"Sci Immunol"},{"issue":"6","key":"10.1016\/j.clml.2023.04.007_bib0126","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1007\/s12094-020-02499-0","article-title":"The effect of PD-1 expression on tumor-associated macrophage in T cell lymphoma","volume":"23","author":"Ruan","year":"2021","journal-title":"Clin Transl Oncol"},{"issue":"40","key":"10.1016\/j.clml.2023.04.007_bib0127","doi-asserted-by":"crossref","first-page":"65284","DOI":"10.18632\/oncotarget.11673","article-title":"GATA3 expression correlates with poor prognosis and tumor-associated macrophage infiltration in peripheral T cell lymphoma","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.clml.2023.04.007_bib0128","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1016\/j.celrep.2019.05.041","article-title":"Quantitative interactomics in primary T cells provides a rationale for concomitant PD-1 and BTLA coinhibitor blockade in cancer immunotherapy","volume":"27","author":"Celis-Gutierrez","year":"2019","journal-title":"Cell Rep"},{"issue":"18","key":"10.1016\/j.clml.2023.04.007_bib0129","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMra1514296","article-title":"Molecular and biochemical aspects of the PD-1 checkpoint pathway","volume":"375","author":"Boussiotis","year":"2016","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.clml.2023.04.007_bib0130","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1128\/MCB.00319-13","article-title":"PD-1 increases PTEN phosphatase activity while decreasing PTEN protein stability by inhibiting casein kinase 2","volume":"33","author":"Patsoukis","year":"2013","journal-title":"Mol Cell Biol"},{"issue":"3","key":"10.1016\/j.clml.2023.04.007_bib0131","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41577-019-0224-6","article-title":"TIM3 comes of age as an inhibitory receptor","volume":"20","author":"Wolf","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"10.1016\/j.clml.2023.04.007_bib0132","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1038\/s41588-018-0251-4","article-title":"Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome","volume":"50","author":"Gayden","year":"2018","journal-title":"Nat Genet"},{"key":"10.1016\/j.clml.2023.04.007_bib0133","article-title":"A novel germline HAVCR2 (TIM-3) compound heterozygous mutation is related to hemophagocytic lymphohistiocytic syndrome in EBV-positive peripheral T-cell lymphoma (NOS) with down-regulated TIM-3 signaling","volume":"12","author":"Zhang","year":"2022","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.clml.2023.04.007_bib0134","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/s41590-022-01176-4","article-title":"LAG3 associates with TCR-CD3 complexes and suppresses signaling by driving co-receptor-Lck dissociation","volume":"23","author":"Guy","year":"2022","journal-title":"Nat Immunol"},{"issue":"3","key":"10.1016\/j.clml.2023.04.007_bib0135","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.it.2020.12.008","article-title":"VISTA: a mediator of quiescence and a promising target in cancer immunotherapy","volume":"42","author":"Yuan","year":"2021","journal-title":"Trends Immunol"},{"issue":"1","key":"10.1016\/j.clml.2023.04.007_bib0136","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1907059","article-title":"VISTA and PD-L1 synergistically predict poor prognosis in patients with extranodal natural killer\/T-cell lymphoma","volume":"10","author":"He","year":"2021","journal-title":"Oncoimmunology"},{"issue":"4","key":"10.1016\/j.clml.2023.04.007_bib0137","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1136\/jclinpath-2019-206117","article-title":"Expression of the checkpoint receptors LAG-3, TIM-3 and VISTA in peripheral T cell lymphomas","volume":"73","author":"Murga-Zamalloa","year":"2020","journal-title":"J Clin Pathol"},{"issue":"13","key":"10.1016\/j.clml.2023.04.007_bib0138","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1084\/jem.20140987","article-title":"Gain-of-function CCR4 mutations in adult T cell leukemia\/lymphoma","volume":"211","author":"Nakagawa","year":"2014","journal-title":"J Exp Med"},{"key":"10.1016\/j.clml.2023.04.007_bib0139","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1146\/annurev-immunol-110416-120628","article-title":"Disorders of the JAK\/STAT pathway in T cell lymphoma pathogenesis: implications for immunotherapy","volume":"35","author":"Waldmann","year":"2017","journal-title":"Annu Rev Immunol"},{"issue":"7","key":"10.1016\/j.clml.2023.04.007_bib0140","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2016-01-690701","article-title":"EZH2 phosphorylation by JAK3 mediates a switch to noncanonical function in natural killer\/T-cell lymphoma","volume":"128","author":"Yan","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2023.04.007_bib0141","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/bjh.14984","article-title":"Mutations in the JAK\/STAT pathway genes and activation of the pathway, a relevant finding in nodal Peripheral T-cell lymphoma","volume":"183","author":"Manso","year":"2018","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.clml.2023.04.007_bib0142","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41408-018-0138-8","article-title":"Prognostic and therapeutic significance of phosphorylated STAT3 and protein tyrosine phosphatase-6 in peripheral-T cell lymphoma","volume":"8","author":"Han","year":"2018","journal-title":"Blood Cancer J"},{"issue":"26","key":"10.1016\/j.clml.2023.04.007_bib0143","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood.2021013379","article-title":"A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK\/STAT targeting in T-cell lymphomas","volume":"138","author":"Moskowitz","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2023.04.007_bib0144","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.semdp.2016.11.002","article-title":"A new molecular paradigm in mycosis fungoides and Sezary syndrome","volume":"34","author":"Elenitoba-Johnson","year":"2017","journal-title":"Semin Diagn Pathol"},{"key":"10.1016\/j.clml.2023.04.007_bib0145","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.775363","article-title":"Advanced pathogenetic concepts in T-cell prolymphocytic leukemia and their translational impact","volume":"11","author":"Braun","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2023.04.007_bib0146","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3389\/fonc.2020.00152","article-title":"Insights into genetic landscape of large granular lymphocyte leukemia","volume":"10","author":"Teramo","year":"2020","journal-title":"Front oncol"},{"issue":"25","key":"10.1016\/j.clml.2023.04.007_bib0147","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1182\/blood-2013-05-506386","article-title":"Deep sequencing of the T-cell receptor repertoire in CD8+ T-large granular lymphocyte leukemia identifies signature landscapes","volume":"122","author":"Clemente","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2023.04.007_bib0148","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1158\/2159-8290.CD-16-0330","article-title":"The Genetic Basis of Hepatosplenic T-cell Lymphoma","volume":"7","author":"McKinney","year":"2017","journal-title":"Cancer Discov"},{"issue":"19","key":"10.1016\/j.clml.2023.04.007_bib0149","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.1182\/bloodadvances.2020001782","article-title":"Whole-genome sequencing reveals potent therapeutic strategy for monomorphic epitheliotropic intestinal T-cell lymphoma","volume":"4","author":"Huang","year":"2020","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.clml.2023.04.007_bib0150","doi-asserted-by":"crossref","DOI":"10.15252\/embr.201846944","article-title":"SWI\/SNF chromatin remodeling controls Notch-responsive enhancer accessibility","volume":"20","author":"Pillidge","year":"2019","journal-title":"EMBO Rep"},{"issue":"1","key":"10.1016\/j.clml.2023.04.007_bib0151","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1038\/s41467-020-17959-y","article-title":"Interaction of the pioneer transcription factor GATA3 with nucleosomes","volume":"11","author":"Tanaka","year":"2020","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.clml.2023.04.007_bib0152","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4049\/jimmunol.1700559","article-title":"The loss of tet2 promotes CD8(+) T cell memory differentiation","volume":"200","author":"Carty","year":"2018","journal-title":"J Immunol"},{"issue":"24","key":"10.1016\/j.clml.2023.04.007_bib0153","doi-asserted-by":"crossref","first-page":"eabm4982","DOI":"10.1126\/sciadv.abm4982","article-title":"Tet2 coordinates with Foxo1 and Runx1 to balance T follicular helper cell and T helper 1 cell differentiation","volume":"8","author":"Baessler","year":"2022","journal-title":"Sci Adv"},{"key":"10.1016\/j.clml.2023.04.007_bib0154","article-title":"Aging drives Tet2+\/- clonal hematopoiesis via IL-1 signaling","author":"Caiado","year":"2022","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.clml.2023.04.007_bib0155","doi-asserted-by":"crossref","DOI":"10.1172\/JCI139675","article-title":"Chronic T cell receptor stimulation unmasks NK receptor signaling in peripheral T cell lymphomas via epigenetic reprogramming","volume":"131","author":"Carras","year":"2021","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.clml.2023.04.007_bib0156","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.immuni.2014.04.006","article-title":"Downmodulation of tumor suppressor p53 by T cell receptor signaling is critical for antigen-specific CD4(+) T cell responses","volume":"40","author":"Watanabe","year":"2014","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/j.clml.2023.04.007_bib0157","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1182\/blood.V99.8.2929","article-title":"The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells","volume":"99","author":"Berger","year":"2002","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2023.04.007_bib0158","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.ccell.2021.08.011","article-title":"The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma","volume":"39","author":"Steen","year":"2021","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.clml.2023.04.007_bib0159","doi-asserted-by":"crossref","DOI":"10.15252\/embr.202357070","article-title":"Multinucleation resets human macrophages for specialized functions at the expense of their identity","volume":"24","author":"Ahmadzadeh","year":"2023","journal-title":"EMBO Rep"},{"issue":"6","key":"10.1016\/j.clml.2023.04.007_bib0160","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/j.1365-2559.2011.04069.x","article-title":"Revising the historical collection of epithelioid cell-rich lymphomas of the Kiel Lymph Node Registry: what is Lennert's lymphoma nowadays?","volume":"59","author":"Hartmann","year":"2011","journal-title":"Histopathology"},{"issue":"5","key":"10.1016\/j.clml.2023.04.007_bib0161","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1046\/j.1365-2141.2003.04335.x","article-title":"Angioimmunoblastic T-cell lymphoma","volume":"121","author":"Dogan","year":"2003","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.clml.2023.04.007_bib0162","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/ajcp\/aqaa227","article-title":"Reactive eosinophil proliferations in tissue and the lymphocytic variant of hypereosinophilic syndrome","volume":"155","author":"King","year":"2021","journal-title":"Am J Clin Pathol"},{"issue":"9","key":"10.1016\/j.clml.2023.04.007_bib0163","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.leukres.2008.02.016","article-title":"TARC and IL-5 expression correlates with tissue eosinophilia in peripheral T-cell lymphomas","volume":"32","author":"Thielen","year":"2008","journal-title":"Leuk Res"},{"issue":"1","key":"10.1016\/j.clml.2023.04.007_bib0164","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ccell.2022.11.014","article-title":"IL-5-producing CD4(+) T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer","volume":"41","author":"Blomberg","year":"2023","journal-title":"Cancer Cell"},{"issue":"13","key":"10.1016\/j.clml.2023.04.007_bib0165","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1182\/blood-2008-05-155937","article-title":"Mature human eosinophils express functional Notch ligands mediating eosinophil autocrine regulation","volume":"113","author":"Radke","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2023.04.007_bib0166","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/path.4898","article-title":"TET2 mutations in B cells of patients affected by angioimmunoblastic T-cell lymphoma","volume":"242","author":"Schwartz","year":"2017","journal-title":"J Pathol"},{"issue":"1","key":"10.1016\/j.clml.2023.04.007_bib0167","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1056\/NEJMc1111708","article-title":"TET2 and DNMT3A mutations in human T-cell lymphoma","volume":"366","author":"Couronne","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clml.2023.04.007_bib0168","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/ng.2872","article-title":"Somatic RHOA mutation in angioimmunoblastic T cell lymphoma","volume":"46","author":"Sakata-Yanagimoto","year":"2014","journal-title":"Nat Genet"},{"issue":"12","key":"10.1016\/j.clml.2023.04.007_bib0169","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1158\/2159-8290.CD-18-0657","article-title":"TET2 deficiency causes germinal center hyperplasia, impairs plasma cell differentiation, and promotes B-cell lymphomagenesis","volume":"8","author":"Dominguez","year":"2018","journal-title":"Cancer Discov"},{"issue":"25","key":"10.1016\/j.clml.2023.04.007_bib0170","doi-asserted-by":"crossref","first-page":"eaay5872","DOI":"10.1126\/sciadv.aay5872","article-title":"TET2 deficiency reprograms the germinal center B cell epigenome and silences genes linked to lymphomagenesis","volume":"6","author":"Rosikiewicz","year":"2020","journal-title":"Sci Adv"},{"issue":"7569","key":"10.1016\/j.clml.2023.04.007_bib0171","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/nature15252","article-title":"Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6","volume":"525","author":"Zhang","year":"2015","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.clml.2023.04.007_bib0172","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/nm.3337","article-title":"CSF-1R inhibition alters macrophage polarization and blocks glioma progression","volume":"19","author":"Pyonteck","year":"2013","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.clml.2023.04.007_bib0173","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1158\/1078-0432.CCR-14-0830","article-title":"Reduction of regulatory T cells by mogamulizumab, a defucosylated Anti-CC chemokine receptor 4 antibody, in patients with aggressive\/refractory mycosis fungoides and sezary syndrome","volume":"21","author":"Ni","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.clml.2023.04.007_bib0174","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1182\/blood-2015-02-625251","article-title":"Mogamulizumab: 2 birds, 1 stone","volume":"125","author":"Wilcox","year":"2015","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.clml.2023.04.007_bib0175","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1182\/blood.2019001744","article-title":"Targeted inhibition of CD47-SIRPalpha requires Fc-FcgammaR interactions to maximize activity in T-cell lymphomas","volume":"134","author":"Jain","year":"2019","journal-title":"Blood"},{"issue":"7629","key":"10.1016\/j.clml.2023.04.007_bib0176","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nature19834","article-title":"PI3Kgamma is a molecular switch that controls immune suppression","volume":"539","author":"Kaneda","year":"2016","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.clml.2023.04.007_bib0177","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S1074-7613(00)80115-6","article-title":"Impaired NFATc translocation and failure of Th2 development in Itk-deficient CD4+ T cells","volume":"11","author":"Fowell","year":"1999","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.clml.2023.04.007_bib0178","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.immuni.2004.06.009","article-title":"Signaling through Itk promotes T helper 2 differentiation via negative regulation of T-bet","volume":"21","author":"Miller","year":"2004","journal-title":"Immunity"},{"issue":"9","key":"10.1016\/j.clml.2023.04.007_bib0179","doi-asserted-by":"crossref","first-page":"E966","DOI":"10.1073\/pnas.1500712112","article-title":"Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK","volume":"112","author":"Sagiv-Barfi","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2023.04.007_bib0180","series-title":"Presented at the Annual Meeting of the","article-title":"Innate Cell Engager AFM13 Combined with Preactivated and Expanded Cord Blood-Derived NK Cells for Patients with Double Refractory CD30+ Lympohma","author":"Nieto","year":"2022"},{"issue":"1","key":"10.1016\/j.clml.2023.04.007_bib0181","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1186\/s13287-021-02595-0","article-title":"CAR-T cell therapy in T-cell malignancies: Is success a low-hanging fruit?","volume":"12","author":"Safarzadeh Kozani","year":"2021","journal-title":"Stem Cell Res Ther"},{"issue":"8","key":"10.1016\/j.clml.2023.04.007_bib0182","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human chimeric antigen receptor macrophages for cancer immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat Biotechnol"},{"issue":"8","key":"10.1016\/j.clml.2023.04.007_bib0183","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1002\/ajh.26270","article-title":"Aggressive T-cell lymphomas: 2021 Updates on diagnosis, risk stratification and management","volume":"96","author":"Zain","year":"2021","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.clml.2023.04.007_bib0184","doi-asserted-by":"crossref","first-page":"285","DOI":"10.6004\/jnccn.2022.0015","article-title":"T-Cell Lymphomas, version 2.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Horwitz","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"10.1016\/j.clml.2023.04.007_bib0185","first-page":"293","article-title":"Current treatment of peripheral T-cell lymphoma","volume":"36","author":"Stuver","year":"2022","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.clml.2023.04.007_bib0186","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-019-0473-1","article-title":"Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling","author":"Watatani","year":"2019","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.clml.2023.04.007_bib0187","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1182\/blood-2016-03-707141","article-title":"Integrated mate-pair and RNA sequencing identifies novel, targetable gene fusions in peripheral T-cell lymphoma","volume":"128","author":"Boddicker","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2023.04.007_bib0188","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/leu.2014.261","article-title":"Targeted mutational profiling of peripheral T-cell lymphoma not otherwise specified highlights new mechanisms in a heterogeneous pathogenesis","volume":"29","author":"Schatz","year":"2015","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.clml.2023.04.007_bib0189","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1073\/pnas.1608839114","article-title":"Activating mutations and translocations in the guanine exchange factor VAV1 in peripheral T-cell lymphomas","volume":"114","author":"Abate","year":"2017","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"11","key":"10.1016\/j.clml.2023.04.007_bib0190","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1182\/blood-2016-02-698977","article-title":"Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas","volume":"128","author":"Vallois","year":"2016","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2023.04.007_bib0191","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1182\/blood-2013-10-531509","article-title":"A targeted mutational landscape of angioimmunoblastic T-cell lymphoma","volume":"123","author":"Odejide","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2023.04.007_bib0192","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/ng.2873","article-title":"Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas","volume":"46","author":"Palomero","year":"2014","journal-title":"Nat Genet"},{"issue":"15","key":"10.1016\/j.clml.2023.04.007_bib0193","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1182\/blood-2013-04-497933","article-title":"PRDM1\/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma","volume":"122","author":"Boi","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2023.04.007_bib0194","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.3324\/haematol.2019.238766","article-title":"Whole Exome Sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target","volume":"106","author":"Larose","year":"2021","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.clml.2023.04.007_bib0195","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1182\/blood-2014-04-571091","article-title":"ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes","volume":"124","author":"Parrilla Castellar","year":"2014","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023001349?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023001349?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:42:39Z","timestamp":1761871359000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023001349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":195,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S2152265023001349"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.04.007","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions | New Pathways and New Targets in PTCL: Staying on Target","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}